Urine proteomics defines an immune checkpoint-associated nephritis signature
Journal for ImmunoTherapy of Cancer · 2025
DOI: 10.1136/jitc-2024-010680 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von James P Long und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, Division of Discovery Science, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Proteomics, Nephritis, Nephritis, Interstitial. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, NCI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Immune checkpoint inhibitor (ICI) therapy is a cornerstone treatment for many cancers, but it can induce severe immunotoxicity, including acute interstitial nephritis (AIN). Currently, kidney biopsy is required to differentiate ICI-AIN from other causes of acute kidney injury (AKI). However, this invasive approach can lead to morbidity, delayed glucocorticoid treatment for patients with AIN, and unnecessarily prolonged suspension of ICI therapy in non-AIN patients. Delayed or incorrect diagnosis of ICI-AIN is particularly detrimental, as over 50% of patients are at risk of permanent renal damage. Thus, there is an urgent need for non-invasive biomarkers that can rapidly and accurately distinguish ICI-AIN from other causes of AKI. The urine and plasma proteome contain actively secreted proteins that provide real-time insights into dynamic physiological processes. However, identification of effective biomarkers of disease using established technologies such as proximity ligation assays (PLA) and bead-based immunoassays is challenging due to their limited sensitivity and loss of precision in multiplex analysis. To address this, we employed cutting-edge NUcleic acid Linked Immuno-Sandwich Assay (NULISA) technology to measure protein expression in urine and plasma samples from AKI patients undergoing ICI therapy. NULISA offers 10,000-fold greater precision than PLA, enabling quantification of over 200 inflammatory proteins with unprecedented precision. Our analysis revealed that urine was more sensitive and specific than plasma in distinguishing ICI-AIN from non-AIN cases. Pathway analyses highlighted the involvement of JAK-STAT and tumor necrosis factor (TNF) signaling in ICI-AIN pathogenesis. We identified several novel urine biomarkers, including IL-5, Fas, TNFSF4, CD274, IL-20, TNFSF15, TSLP, TREM1 and CCL1 while confirming previously reported markers such as CXCL9 and TNF-α. Using statistical and machine learning methods, we constructed a novel urine biomarker signature—IL-5+Fas—that achieved an area under the curve of 0.94 for diagnosing ICI-AIN. By leveraging high-sensitivity proteomics, we developed a non-invasive strategy for diagnosing ICI-AIN. This approach will enable earlier intervention to mitigate immunotoxicity, preservation of antitumor efficacy of ICI therapy in non-AIN patients, and safe rechallenge of ICI therapy in patients previously treated for ICI-AIN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biostatistics, Division of Discovery Science, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA cassianyee@me.com jlin8@mdanderson.org.
- Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA cassianyee@me.com jlin8@mdanderson.org.
Förderung
- NIDDK NIH HHS
- NCI NIH HHS
- NCATS NIH HHS
- Division of Loan Repayment
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences
- Center for Cancer Research
Zitieren
APA
Long, J. P., Singh, S., Dong, Y., Yee, C., & Lin, J. S. (2025). Urine proteomics defines an immune checkpoint-associated nephritis signature. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-010680
Vancouver
Long JP, Singh S, Dong Y, Yee C, Lin JS. Urine proteomics defines an immune checkpoint-associated nephritis signature. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2024-010680
BibTeX
@article{Long2025,
author = {Long, James P and Singh, Shailbala and Dong, Yanlan and Yee, Cassian and Lin, Jamie S},
title = {Urine proteomics defines an immune checkpoint-associated nephritis signature},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
doi = {10.1136/jitc-2024-010680}
}
EUVIMED